Stuart Madden
About Stuart Madden
Stuart Madden is the Chief Scientific Officer at Neurelis with over 30 years of experience in the pharmaceutical industry, specializing in drug development programs.
Stuart Madden's Title and Role
Stuart Madden serves as the Chief Scientific Officer at Neurelis. He has been with the company since 2008, initially in a supporting role for the development of VALTOCO. In July 2020, he transitioned to a full-time employee status. His responsibilities likely include overseeing scientific research, drug development, and strategic scientific initiatives within the organization.
Stuart Madden's Extensive Pharmaceutical Industry Experience
Stuart Madden brings over 30 years of experience in the pharmaceutical industry. His career includes significant roles in both large pharmaceutical companies and specialized biotech firms. Earlier in his career, Madden worked with Mallinckrodt and Schering Plough. From 1995 to 2003, he was at Elan Corporation, focusing on developing and commercializing controlled-release oral dosage forms. He then moved to ICON Clinical Research in 2003, where he served as Vice President of Scientific Affairs, providing strategic consulting expertise to biotech and pharmaceutical clients.
Stuart Madden's Education and Professional Credentials
Stuart Madden received his Bachelor of Science degree in chemistry and his Ph.D. in physical chemistry from the University of Wales, Swansea, UK. He pursued postdoctoral work for two years at San Diego State University in California. Madden is recognized as a Chartered Chemist and is a Fellow of the Royal Society of Chemistry. These credentials underscore his deep expertise in chemistry and his commitment to maintaining high professional standards.
Stuart Madden's Role in Drug Development and Advisory Positions
Stuart Madden has been instrumental in drug development throughout his career. At Neurelis, he supported the development of VALTOCO. His previous experience includes work at ICON Clinical Research and Elan Corporation, where he focused on strategic consulting and controlled-release oral dosage forms, respectively. Additionally, Madden served as a special government employee for the FDA's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology, providing insights and guidance based on his extensive industry knowledge.